公开(公告)号：US10294304B2

公开(公告)日：2019-05-21

申请号：US15085317

申请日：2016-03-30

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien Kuo ,  Bijan Andre Boldajipour ,  Javier Fernando Chaparro Riggers ,  Philippe Duchateau ,  Roman Galetto ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Arvind Rajpal ,  Barbra Johnson Sasu ,  Cesar Adolfo Sommer ,  Julien Valton ,  Thomas John Van Blarcom

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/63 ,  C07K14/725 ,  C07K14/705 ,  A61K39/00 ,  A61K31/7076 ,  A61K35/17 ,  A61K38/00

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

公开(公告)号：US11912776B2

公开(公告)日：2024-02-27

申请号：US17695769

申请日：2022-03-15

Applicant: Pfizer Inc.

Inventor： Tracy Chia-Chien Kuo ,  Bijan Andre Boldajipour ,  Javier Fernando Chaparro Riggers ,  Philippe Duchateau ,  Roman Galetto ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Arvind Rajpal ,  Barbra Johnson Sasu ,  Cesar Adolfo Sommer ,  Julien Valton ,  Thomas John Van Blarcom

IPC: C07K14/705 ,  C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  C12N5/10 ,  C07K14/725 ,  A61K31/7076 ,  C12N15/63 ,  A61K35/17 ,  C12N5/0783 ,  A61K38/00

CPC classification number: C07K16/2878 ,  A61K31/7076 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/46 ,  A61K39/4631 ,  A61K39/464417 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2896 ,  C12N5/0636 ,  C12N5/10 ,  C12N15/63 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K16/2863 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2510/02

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

公开(公告)号：US20220340671A1

公开(公告)日：2022-10-27

申请号：US17695769

申请日：2022-03-15

Applicant: Pfizer Inc.

Inventor： Tracy Chia-Chien KUO ,  Bijan Andre Boldajipour ,  Javier Fernando Chaparro Riggers ,  Philippe Duchateau ,  Roman Galetto ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Arvind Rajpal ,  Barbra Johnson Sasu ,  Cesar Adolfo Sommer ,  Julien Valton ,  Thomas John Van Blarcom

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  A61K39/00 ,  A61K31/7076 ,  C12N15/63 ,  A61K35/17 ,  C12N5/10 ,  C12N5/0783

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

公开(公告)号：US11312782B2

公开(公告)日：2022-04-26

申请号：US16384719

申请日：2019-04-15

Applicant: Pfizer Inc.

Inventor： Tracy Chia-Chien Kuo ,  Bijan Andre Boldajipour ,  Javier Fernando Chaparro Riggers ,  Philippe Duchateau ,  Roman Ariel Galetto ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Arvind Rajpal ,  Barbra Johnson Sasu ,  Cesar Adolfo Sommer ,  Julien Valton ,  Thomas John Van Blarcom

IPC: C12N5/10 ,  C12N15/63 ,  C07K16/28 ,  C07K14/705 ,  C07K19/00 ,  C07K14/725 ,  A61K39/00 ,  A61K31/7076 ,  A61K35/17 ,  C12N5/0783 ,  A61K39/395 ,  A61K38/00

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).